The American Academy of Otolaryngology – Head and Neck Surgery Foundation has added Lenire, a bimodal neuromodulation treatment made by Dublin-based Neuromod Devices, to its updated clinical practice guidelines for tinnitus, according to FinanzNachrichten.de. The announcement was dated 19 October 2026. It is the only new treatment recommendation the academy has introduced since its guidelines first appeared in 2014, the report states.
The guidelines are used by ear, nose and throat specialists across the United States to assess and manage tinnitus in everyday practice. According to FinanzNachrichten.de, they highlight measures and therapies considered beneficial and direct clinicians away from approaches that are time-consuming, costly, hard to access or ineffective.
Why it matters
Tinnitus, the perception of sound without an external source, affects millions of people, and the academy's guidelines carry weight with the physicians who treat them. Because the document had not gained a new treatment recommendation in more than a decade, the addition of a device-based option marks a shift in how the professional body frames care.
The listing builds on the US Food and Drug Administration's 2023 clearance of Lenire, which the company describes as the first and only FDA-authorized device of its kind for bimodal neuromodulation. FinanzNachrichten.de reports that the company sees the guideline inclusion as further establishing Lenire as a new standard of care for tinnitus in the United States.
Neuromod founder Dr. Ross O'Neill called the decision another historic first for the company, its technology and the field of tinnitus treatment. In remarks carried by FinanzNachrichten.de, he said the inclusion means the more than 12,000 practising ENT physicians in the US now have a new safe and effective treatment they can recommend to the millions of Americans living with the condition.
How the device works and what the evidence shows
Lenire pairs sound stimulation with a mild electrical pulse delivered to the surface of the tongue through a proprietary component the company markets as Tonguetip. The two combined inputs are intended to ease tinnitus symptoms. A qualified clinician, such as an ENT doctor or audiologist, prescribes the treatment after a full audiological examination, and patients then carry it out at home as directed.
According to FinanzNachrichten.de, the company says the device has been shown to be effective and inherently safe across three large clinical trials, with results from routine practice adding further support. The FDA clearance in March 2023 rested on a pivotal controlled trial known as TENT-A3 together with confirmatory real-world findings. Those results were published in Nature Communications and rank among the top 1 percent of most-read articles tracked by the journal, the report states.
Two later analyses of patient data from independent clinics were also cited. The first peer-reviewed real-world study, published in Nature Communications Medicine, found that 91.5 percent of tinnitus patients recorded a clinically meaningful reduction in their symptoms. A second retrospective analysis in the American Journal of Audiology reported that 81.8 percent of patients with bothersome tinnitus described a clinically significant improvement.
Professor Hubert Lim, Neuromod's chief scientific officer, said the guideline inclusion supports the depth of clinical evidence behind Lenire for patients seeking help with troublesome tinnitus. He added, according to FinanzNachrichten.de, that the company intends to keep expanding that evidence base so the treatment becomes more effective and more widely available to patients worldwide.
Where the treatment is available
Lenire is offered through qualified medical professionals in the United States, Canada, Europe and Australia, and it is also available as a treatment option through the US Department of Veterans Affairs. Neuromod Devices describes itself as a global medical technology firm with operations in Ireland and North America, focused on designing and developing neuromodulation technologies for the clinical needs of people with tinnitus.
The company has said that tens of thousands of American patients have been treated with Lenire at clinics across the country since the FDA clearance. It plans to help those clinicians continue publishing the growing body of practice data, aiming to cement the device's position as a leading treatment standard.
FinanzNachrichten.de notes that the announcement was issued as a company news release, and that the issuer is responsible for its content.
What to watch next is whether other professional bodies follow the academy's lead and how quickly the published real-world data continues to accumulate.
